Key Developments: JW Holdings Corp (096760.KS)

096760.KS on Korea Stock Exchange

5,800.00KRW
30 Apr 2015
Change (% chg)

-- (--)
Prev Close
₩5,800.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
430,579
52-wk High
₩6,000.00
52-wk Low
₩2,061.90

Search Stocks

Latest Key Developments (Source: Significant Developments)

JW Holdings declares annual cash dividend for 2014
Friday, 27 Feb 2015 02:36am EST 

JW Holdings Corp:To pay annual cash dividend of 25 won per share for 2014 to shareholders of record on Dec. 31, 2014.Total dividend amount of 1,336,260,275 won.  Full Article

JW Holdings Corp announces issuance of bonus share
Tuesday, 16 Dec 2014 01:48am EST 

JW Holdings Corp:Says the issuance of bonus shares in a ratio of 0.05:1 (0.05 bonus share for each share held) to all shareholders of record on Jan. 1, 2015.To total issue 2,672,520 shares.New shares will be listed on Jan. 19, 2015.  Full Article

JW Holdings Corp declares annual cash dividend for FY 2013
Wednesday, 19 Feb 2014 02:30am EST 

JW Holdings Corp:To pay annual cash dividend of 25 won per share for fiscal year 2013 on April 18, to shareholders of record on Dec. 31, 2013.Says total dividend amount of 1,272,671,375 won.  Full Article

JW Holdings Corp announces issuance of bonus shares
Monday, 16 Dec 2013 12:48am EST 

JW Holdings Corp:Says to issue bonus shares to shareholders of record on Jan. 1, 2014, in a ratio of 0.05:1 (0.05 bonus share for each share held).Says totally 2,545,342 common shares of par value 500 won each will be issued as bonus shares * Says listing date of Jan. 20, 2014 for the new shares.  Full Article

Baxter International Inc Announces Development And Commercialization Collaboration For Omega 3 Parenteral Nutrition Products With JW Holdings Corp
Wednesday, 31 Jul 2013 01:38am EDT 

Baxter International Inc and JW Holdings announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a formulation of omega 3 lipids. With this collaboration, Baxter will complement global parenteral nutrition portfolio, and provide global commercial capabilities and clinical development. Under the terms of the agreement, Baxter will have exclusive rights to co-develop and distribute the products globally, with the exception of Korea. The arrangement includes a $25 million up-front payment that will be recorded as a special pre-tax in-process research and development charge in the third quarter of 2013. Additionally, the agreement calls for payments totaling up to $10 million for the achievement of regulatory milestones, along with royalties on future product sales. The agreement remains in effect for 10 years following the product launch outside of Korea. The companies will share equally in the development costs and global clinical trials and registrations. JW Holdings will manufacture the products in Dangjin, Korea facility. Additionally, Baxter has specified rights to certain additional nutritional products that JW Holdings may develop or produce in the future.  Full Article

JW Holdings Corp to Jointly Develop Generic Medicine
Monday, 8 Jul 2013 08:37pm EDT 

JW Holdings Corp announced that it will jointly research and develop generic medicine with Japan-based Sanwa Kagaku Kenkyusho Corporation, to make inroads into Japan generic market.  Full Article

JW Holdings Corp to Sell Shares of JW Life Science
Friday, 14 Jun 2013 04:26am EDT 

JW Holdings Corp announced that it has sold 3,662,817 shares of JW Life Science for KRW 91 billion on June 14, 2013. After the transaction, the Company still holds 2,375,183 shares of JW Life Science, representing a 39.34% stake.  Full Article

Search Stocks